文献速递肿瘤 PET/CT放射性药物与辐射防护

应用[18F]FDG-PET/CT与增强CT无创评估和量化可调控血管生成的肿瘤模型中的肿瘤血管化

Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis-an animal experimental prospective cohort study.
PubMed 文献 · EJNMMI Res · 2019-06-21

本研究在71只无胸腺裸鼠中建立可调控血管化的人非小细胞肺癌异种移植瘤模型,采用临床[18F]FDG-PET/CT和增强CT无创评估肿瘤血管化,并与组织学对照。结果显示共移植大鼠肾小球内皮细胞(RGE)的肿瘤生长更快、微血管密度更高、灌注更多,且[18F]FDG PET/CT的SUVmax和代谢活性体积显著更高;影像参数与组织学血管化指标及CE-CT参数显著相关。结论提示[18F]FDG-PET/CT和CE-CT能无创检测与肿瘤血管化程度密切相关的参数。

要点

  • 共移植RGE细胞可增加肿瘤血管化并提高[18F]FDG摄取。
  • [18F]FDG PET/CT参数与组织学血管化指标及CE-CT参数显著相关。
  • [18F]FDG PET/CT和CE-CT可无创评估肿瘤血管化程度。

核心结论

  • 成功建立了适用于影像、药理学和放射治疗研究的人异种移植瘤模型,其血管化程度可调控。
  • [18F]FDG-PET/CT和CE-CT均能检测与肿瘤血管化程度密切相关的参数,有助于无创评估肿瘤血管化。
  • [18F]FDG-PET可考虑用于超越单纯葡萄糖代谢的肿瘤表征,对肿瘤诊断有更大贡献。

研究设计与样本

  • 在71只无胸腺裸鼠中皮下移植人非小细胞肺癌(NSCLC)细胞建立可调控血管化的异种移植瘤模型。
  • 四个移植组分别单独移植两种肿瘤细胞系(A549或H1299),或与鼠肾小球内皮(RGE)细胞共移植以增加血管化。
  • 采用临床扫描仪进行[18F]FDG PET/CT和增强CT(CE-CT)无创评估,随后行组织学检查评估肿瘤血管(CD-31和血管内荧光微球)。

主要发现

  • 两种肿瘤细胞系中,共移植RGE细胞均导致更快的生长速率[最大肿瘤直径达20 mm所需时间22(±1.2)天对比45(±1.8)天,p < 0.001]。
  • 共移植RGE细胞组组织学CD-31染色微血管密度更高[171.4(±18.9)对比110.8(±11)血管/mm²,p = 0.002],灌注微球数更多[1.3(±0.1)对比1.1(±0.04)微球/视野,p = 0.001]。
  • [18F]FDG-PET/CT中,共移植组SUVmax显著更高[2.8(±0.2)对比1.1(±0.1),p < 0.001],代谢活性体积更大[2.4(±0.2)对比0.4(±0.2)cm³,p < 0.001]。
  • 组织学血管化参数与[18F]FDG PET/CT参数显著相关[微球与SUVmax,r = 0.353,p = 0.005;CD-31与SUVmax,r = 0.294,p = 0.036]。
  • CE-CT与[18F]FDG PET/CT参数显著相关[对比增强与SUVmax,r = 0.63,p < 0.001;活性CT肿瘤体积与代谢PET肿瘤体积,r = 0.919,p < 0.001]。

临床怎么用

  • [18F]FDG-PET/CT和CE-CT可用于无创评估肿瘤血管化程度,辅助肿瘤表征。
  • 在临床前研究中,该可调控血管化模型可用于影像、药理学和放射治疗研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the noninvasive assessment of tumor vascularization with clinical F-18-fluorodeoxyglucose positron emission tomography/computed tomography and contrast-enhanced computed tomography ([18F]FDG-PET/CT and CE-CT) in experimental human xenograft tumors with modifiable vascularization and compared results to histology. Tumor xenografts with modifiable vascularization were established in 71 athymic nude rats by subcutaneous transplantation of human non-small-cell lung cancer (NSCLC) cells. Four different groups were transplanted with two different tumor cell lines (either A549 or H1299) alone or tumors co-transplanted with rat glomerular endothelial (RGE) cells, the latter to increase vascularization. Tumors were assessed noninvasively by [18F]FDG PET/CT and contrast-enhanced CT (CE-CT) using clinical scanners. This was followed by histological examinations evaluating tumor vasculature (CD-31 and intravascular fluorescent beads). RESULTS: In both tumor lines (A549 and H1299), co-transplantation of RGE cells resulted in faster growth rates [maximal tumor diameter of 20 mm after 22 (± 1.2) as compared to 45 (± 1.8) days, p < 0.001], higher microvessel density (MVD) determined histologically after CD-31 staining [171.4 (± 18.9) as compared to 110.8 (± 11) vessels per mm2, p = 0.002], and higher perfusion as indicated by the number of beads [1.3 (± 0.1) as compared to 1.1 (± 0.04) beads per field of view, p = 0.001]. In [18F]FDG-PET/CT, co-transplanted tumors revealed significantly higher standardized uptake values [SUVmax, 2.8 (± 0.2) as compared to 1.1 (± 0.1), p < 0.001] and larger metabolic active volumes [2.4 (± 0.2) as compared to 0.4 (± 0.2) cm3, p < 0.001] than non-co-transplanted tumors. There were significant correlations for vascularization parameters derived from histology and [18F]FDG PET/CT [beads and SUVmax, r = 0.353, p = 0.005; CD-31 and SUVmax, r = 0.294, p = 0.036] as well as between CE-CT and [18F]FDG PET/CT [contrast enhancement and SUVmax, r = 0.63, p < 0.001; vital CT tumor volume and metabolic PET tumor volume, r = 0.919, p < 0.001]. CONCLUSIONS: In this study, a human xenograft tumor model with modifiable vascularization implementable for imaging, pharmacological, and radiation therapy studies was successfully established. Both [18F]FDG-PET/CT and CE-CT are capable to detect parameters closely connected to the degree of tumor vascularization, thus they can help to evaluate vascularization in tumors noninvasively. [18F]FDG-PET may be considered for characterization of tumors beyond pure glucose metabolism and have much greater contribution to diagnostics in oncology.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mirus M, Tokalov SV, Abramyuk A, et al. Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis-an animal experimental prospective cohort study. EJNMMI Res. 2019. PMID: 31227938. doi:10.1186/s13550-019-0502-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。